BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,498,855 | -26.8% | 286,453 | -12.2% | 0.02% | -21.9% |
| Q2 2023 | $26,627,134 | -48.8% | 326,193 | -53.5% | 0.03% | -52.2% |
| Q1 2023 | $52,005,482 | +3.4% | 700,977 | +15.5% | 0.07% | -5.6% |
| Q4 2022 | $50,294,152 | +8.1% | 606,831 | +270.4% | 0.07% | +6.0% |
| Q3 2022 | $46,532,832 | -19.6% | 163,848 | -1.9% | 0.07% | -54.1% |
| Q2 2022 | $57,879,000 | -23.6% | 166,971 | -4.5% | 0.15% | -7.0% |
| Q1 2022 | $75,724,000 | +29.3% | 174,868 | +54.5% | 0.16% | +40.2% |
| Q4 2021 | $58,559,000 | -21.4% | 113,194 | -26.4% | 0.11% | -24.8% |
| Q3 2021 | $74,496,000 | +576.3% | 153,736 | +528.4% | 0.15% | +609.5% |
| Q2 2021 | $11,015,000 | +44.7% | 24,463 | +22.8% | 0.02% | +40.0% |
| Q1 2021 | $7,612,000 | +17.4% | 19,929 | -2.4% | 0.02% | +15.4% |
| Q4 2020 | $6,483,000 | +23.6% | 20,415 | -3.6% | 0.01% | +8.3% |
| Q3 2020 | $5,246,000 | -14.1% | 21,178 | -8.4% | 0.01% | -14.3% |
| Q2 2020 | $6,107,000 | +60.2% | 23,129 | +15.1% | 0.01% | +40.0% |
| Q1 2020 | $3,811,000 | -14.7% | 20,095 | -1.3% | 0.01% | +11.1% |
| Q4 2019 | $4,470,000 | +48.7% | 20,365 | +32.5% | 0.01% | +28.6% |
| Q3 2019 | $3,007,000 | +5.7% | 15,368 | +12.7% | 0.01% | +16.7% |
| Q2 2019 | $2,844,000 | +32.2% | 13,639 | +25.8% | 0.01% | +20.0% |
| Q1 2019 | $2,152,000 | +29.5% | 10,841 | -5.6% | 0.01% | +25.0% |
| Q4 2018 | $1,662,000 | -28.9% | 11,481 | +0.2% | 0.00% | -20.0% |
| Q3 2018 | $2,338,000 | +35.1% | 11,456 | -2.1% | 0.01% | +25.0% |
| Q2 2018 | $1,731,000 | -14.4% | 11,697 | -12.7% | 0.00% | 0.0% |
| Q1 2018 | $2,023,000 | +15.5% | 13,391 | -1.0% | 0.00% | 0.0% |
| Q4 2017 | $1,752,000 | +2.9% | 13,526 | -4.0% | 0.00% | 0.0% |
| Q3 2017 | $1,703,000 | +1.7% | 14,088 | -1.1% | 0.00% | 0.0% |
| Q2 2017 | $1,674,000 | +11.6% | 14,244 | -3.5% | 0.00% | +33.3% |
| Q1 2017 | $1,500,000 | -5.8% | 14,753 | -4.7% | 0.00% | -25.0% |
| Q4 2016 | $1,592,000 | -11.3% | 15,485 | -5.5% | 0.00% | +33.3% |
| Q3 2016 | $1,794,000 | -0.2% | 16,383 | +2.8% | 0.00% | -25.0% |
| Q2 2016 | $1,797,000 | +39.3% | 15,933 | +16.8% | 0.00% | +33.3% |
| Q1 2016 | $1,290,000 | +4.5% | 13,646 | -0.4% | 0.00% | 0.0% |
| Q4 2015 | $1,234,000 | -6.9% | 13,707 | -4.4% | 0.00% | 0.0% |
| Q3 2015 | $1,326,000 | -8.0% | 14,339 | -2.1% | 0.00% | 0.0% |
| Q2 2015 | $1,442,000 | -8.1% | 14,642 | -6.4% | 0.00% | 0.0% |
| Q1 2015 | $1,569,000 | +8.4% | 15,642 | -0.1% | 0.00% | 0.0% |
| Q4 2014 | $1,447,000 | – | 15,660 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |